Antioxidants in bipolar disorder: A double blind randomised placebo controlled trial of n-acetyl cysteine.

Antioxidants in Bipolar Disorder: A double blind randomised placebo controlled trial investigating n-acetyl cysteine effects on a range of psychiatric rating scales

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000362695

Enrollment

Registered

2005-09-12

Start date

2004-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

This is a six month treatment study with a four to six week post-discontinuation visit. The trial involves 2g of n-acetyl cysteine per day in addition to the participants usual treatment.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

DSM-IV diagnosis of bipolar disorder (I, II or NOS), have had at least one mood episode within the last 12 months, have been on stable treatment for one month, have the capacity to consent and be on effective contraception.

Exclusion criteria

Asthma, history of ulcers, respiritory insufficiency, any current systemic medical disorder, participants who are currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day and women pregnant or lactacting.

Outcome results